Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 13/20 | 0.57 |
| ▸ | PDE5A | O76074 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115062 | 0.90 | PRKCI (0.53) | PRKCIPDE5APTGS1TBXAS1PTGS2 | |
| SCHEMBL5122356 | 0.89 | PRKCI (0.60) | PRKCIPDE5APRKCZ | |
| SCHEMBL5119678 | 0.89 | PRKCI (0.68) | PRKCIPDE5APTGS1TBXAS1PTGS2 | |
| SCHEMBL5118967 | 0.88 | ALDH1A1 (0.57) | PDE5APTGS1TBXAS1PTGS2PDE4A | |
| SCHEMBL5129890 | 0.86 | PRKCI (0.51) | PRKCIADORA2AADORA1 | |
| SCHEMBL8183275 | 0.86 | CYP1A2 (0.49) | PRKCIPDE5APTGS2ADORA2AADORA1 | |
| SCHEMBL5131068 | 0.84 | PDE5A (0.52) | PRKCIPDE5APDE4APDE4BPDE4C | |
| SCHEMBL5122140 | 0.83 | MEN1 (0.55) | PDE5AADORA2AADORA1 | |
| SCHEMBL8170976 | 0.83 | CA1 (0.47) | PRKCIPDE5ACDC7DBF4ESR1 | |
| SCHEMBL5122690 | 0.83 | ADORA2A (0.46) | PRKCIPDE5APTGS1TBXAS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-6432950-B1 | ANTICANCER AGENTS; KILLING CANCER CELLS | CELL PATHWAYS | 2002-08-13 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | PRKCI 1513/4885PDE5A 2002/4885PTGS1 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.